The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.

Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE

Open source

DOI: 10.1016/j.ejca.2025.116162
Published: 2026 Jan 17
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.116162,
  title = {The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.},
  author = {Lorigan P and Medina TM and Nyakas M and Rutten A and Feun LG and Cowey CL and Payne M and Hussain I and Kuzel T and O'Day S and Sheri A and Friedlander PA and Kumar S and Bergersen VS and Foss Ø and Ellingsen EB and Bjørheim J and Bechter OE},
  year = {2026},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.116162},
  url = {https://doi.org/10.1016/j.ejca.2025.116162}
}

RIS

TY  - JOUR
TI  - The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.
AU  - Lorigan P
AU  - Medina TM
AU  - Nyakas M
AU  - Rutten A
AU  - Feun LG
AU  - Cowey CL
AU  - Payne M
AU  - Hussain I
AU  - Kuzel T
AU  - O'Day S
AU  - Sheri A
AU  - Friedlander PA
AU  - Kumar S
AU  - Bergersen VS
AU  - Foss Ø
AU  - Ellingsen EB
AU  - Bjørheim J
AU  - Bechter OE
PY  - 2026
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.116162
UR  - https://doi.org/10.1016/j.ejca.2025.116162
ER  -

APA

P, L., TM, M., M, N., A, R., LG, F., CL, C., M, P., I, H., T, K., S, O., A, S., PA, F., S, K., VS, B., Ø, F., EB, E., J, B., & OE, B. (2026). The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.116162

Source records

pubmed · retrieved 2026-09-27T01:16:26.296Z
europe-pmc · retrieved 2026-09-27T01:16:26.307Z